BioNTech settles royalty dispute with NIH for $791.5 million

BioNTech SE ( (BNTX) ) provided an update.

BioNTech SE has settled a dispute with the National Institutes of Health (NIH) over royalties allegedly owed on sales of the COVID-19 vaccine developed in collaboration with Pfizer. The settlement includes paying $791.5 million to the NIH, resolving past claims and adjusting future royalty agreements. The settlement does not involve an admission of liability by BioNTech, and Pfizer has agreed to reimburse $364.5 million of the settlement amount.

More about BioNTech SE

BioNTech SE is a biotechnology company based in Mainz, Germany, primarily known for the development of mRNA-based vaccines and immunotherapies. The company is an important player in the pharmaceutical industry, particularly known for its collaboration with Pfizer in the production of the vaccine against COVID-19.

YTD price performance: 7.80%

Average trading volume: 820,259

Consensus Assessment of Technical Sentiment: I sell

Current market cap: $27.28 billion

View more BNTX stock data at TipRanks stock analysis page.